Hyperkalemia (HK)
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) (NCT01810939) | Relypsa, Inc. | 2013-02-01 |
Track Hyperkalemia (HK) automatically
Every clearance here is in the API, with alerts when new ones post.